These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 11470598)
1. Human antibodies as next generation therapeutics. van Dijk MA; van de Winkel JG Curr Opin Chem Biol; 2001 Aug; 5(4):368-74. PubMed ID: 11470598 [TBL] [Abstract][Full Text] [Related]
2. Ribosome display: next-generation display technologies for production of antibodies in vitro. He M; Khan F Expert Rev Proteomics; 2005 Jun; 2(3):421-30. PubMed ID: 16000087 [TBL] [Abstract][Full Text] [Related]
3. The biotechnology and applications of antibody engineering. Rapley R Mol Biotechnol; 1995 Apr; 3(2):139-54. PubMed ID: 7620975 [TBL] [Abstract][Full Text] [Related]
4. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Haurum JS Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535 [TBL] [Abstract][Full Text] [Related]
6. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Presta LG Adv Drug Deliv Rev; 2006 Aug; 58(5-6):640-56. PubMed ID: 16904789 [TBL] [Abstract][Full Text] [Related]
7. Intrabodies as drug discovery tools and therapeutics. Stocks M Curr Opin Chem Biol; 2005 Aug; 9(4):359-65. PubMed ID: 15979379 [TBL] [Abstract][Full Text] [Related]
8. Challenges to production of antibodies in bacteria and yeast. Lee YJ; Jeong KJ J Biosci Bioeng; 2015 Nov; 120(5):483-90. PubMed ID: 25912450 [TBL] [Abstract][Full Text] [Related]
9. Antibodies and genetically engineered related molecules: production and purification. Roque AC; Lowe CR; Taipa MA Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864 [TBL] [Abstract][Full Text] [Related]
10. Antibodies for therapeutic uses and the evolution of biotechniques. Nieri P; Donadio E; Rossi S; Adinolfi B; Podestà A Curr Med Chem; 2009; 16(6):753-79. PubMed ID: 19199935 [TBL] [Abstract][Full Text] [Related]
12. Engineering Antibodies for the Treatment of Infectious Diseases. Fan G; Li J Adv Exp Med Biol; 2017; 1053():207-220. PubMed ID: 29549641 [TBL] [Abstract][Full Text] [Related]
13. The application of transgenic mice for therapeutic antibody discovery. Lee EC; Owen M Methods Mol Biol; 2012; 901():137-48. PubMed ID: 22723098 [TBL] [Abstract][Full Text] [Related]
14. Minimizing the immunogenicity of antibodies for clinical application. Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769 [TBL] [Abstract][Full Text] [Related]
15. [Progression and direction of humanized antibody research]. Lin Y; Yan XY Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Antibodies by Phage Display. Shim H Curr Pharm Des; 2016; 22(43):6538-6559. PubMed ID: 27669967 [TBL] [Abstract][Full Text] [Related]
17. Engineering antibodies for therapy. Adair JR Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872 [TBL] [Abstract][Full Text] [Related]
19. The immunogenicity of human-origin therapeutic antibodies are associated with V gene usage. Hu Z; Cohen S; Swanson SJ Front Immunol; 2023; 14():1237754. PubMed ID: 37720227 [TBL] [Abstract][Full Text] [Related]
20. [Progress of research on genetic engineering antibody and its application in prevention and control of parasitic diseases]. Yao Y; Yu CX Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Aug; 25(4):413-6. PubMed ID: 24358756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]